Phase 2 Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with multiple myeloma that has come back or stopped responding to treatment, and who have already received at least 2 previous treatment plans, including one from a drug class called immunomodulatory drugs and one from a class called proteasome inhibitors.
• People who have previously been treated with anti-CD38 or anti-BCMA therapies (except a specific type called an anti-BCMA T cell engager), as long as their myeloma did not stop responding to anti-CD38 treatment.
• People whose myeloma can be measured through specific blood, urine, or light chain protein tests that show the disease is still active (confirm with trial site for exact thresholds).
• People aged 18 or older.
• Women who are able to become pregnant must agree to use reliable contraception during the trial and for a set period after the last dose of each study drug, and must inform their doctor immediately if pregnancy occurs or is suspected.
• People who are well enough to carry out light daily activities, as assessed by a standard health status scale (confirm with trial site).
• People whose blood counts, kidney function, and liver function meet minimum levels set by the trial (confirm with trial site for exact values).
• People who have or have had another cancer, where that cancer or its treatment is not expected to interfere with this trial's results.
• People with a history of heart disease or previous treatment with heart-affecting drugs, where a doctor's assessment places their heart function at a certain level or better on a standard heart classification scale (confirm with trial site).
• People who are able to understand the study and are willing to sign a consent form.

Who may not be able to join:

• People with active plasma cell leukemia, POEMS syndrome, or amyloidosis.
• People who have had a stem cell transplant within the past 12 weeks, or who currently have active graft-versus-host disease (a complication sometimes seen after transplants).
• People who currently have moderate or severe nerve damage in their hands or feet affecting sensation or movement.
• People who have experienced any level of nerve damage in their hands or feet from a previous anti-BCMA treatment, or who have a history of a serious nerve condition called Guillain-Barré syndrome or related conditions, or severe nerve damage affecting movement.
• People who have previously been treated with an anti-BCMA bispecific T cell engager (a specific type of targeted therapy).
• People who are currently taking part in another clinical trial using an experimental treatment.
• People who have received myeloma treatment or an experimental drug within the 2 weeks before starting this trial, or who are still experiencing side effects from a previous treatment.
• People who have a known or suspected allergy to the study drugs or any of their components, including an adhesive that contains acrylic.
• People who have had certain serious heart or blood vessel events in the past 6 months, such as a heart attack, unstable chest pain, certain heart rhythm problems, a stroke, a blood clot in the lung, or certain other related events.
• People with a known active hepatitis B, hepatitis C, or HIV infection, or any active uncontrolled bacterial, fungal, or viral infection that has not fully cleared at least 14 days before joining.
• People who have had another active cancer within the past 3 years, except for certain skin cancers or other cancers that were treated with the aim of a full cure.
• People who have had major surgery in the past 14 days, or who have a medical, psychiatric, or other condition — including recent or active thoughts of self-harm — that the investigating doctor considers would make participation unsafe or unsuitable.
• People who have received a live vaccine within 30 days before the first dose of the study treatment.

Important: Always verify eligibility with the trial site directly before applying.